Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (25)
Yen-Ching Li, Sung-Han Hsiao, Megumi Murakami, Yang-Hui Huang, Yu-Tzu Chang, Tai-Ho Hung, Yu-Shan Wu, Suresh. V. Ambudkar & Chung-Pu Wu. (2023) Epidermal Growth Factor Receptor Inhibitor Mobocertinib Resensitizes Multidrug-Resistant Cancer Cells by Attenuating the Human ATP-Binding Cassette Subfamily B Member 1 and Subfamily G Member 2. ACS Pharmacology & Translational Science.
Crossref
Crossref
Chung-Pu Wu, Yen-Ching Li, Megumi Murakami, Sung-Han Hsiao, Yun-Chieh Lee, Yang-Hui Huang, Yu-Tzu Chang, Tai-Ho Hung, Yu-Shan Wu & Suresh V. Ambudkar. (2023) Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells. International Journal of Molecular Sciences 24:18, pages 13972.
Crossref
Crossref
Manzoor Ahmad Mir & Hina Qayoom. 2023. Therapeutic potential of Cell Cycle Kinases in Breast Cancer. Therapeutic potential of Cell Cycle Kinases in Breast Cancer
1
22
.
Desh Deepak Singh, Hae-Jeung Lee & Dharmendra Kumar Yadav. (2022) Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer. Frontiers in Pharmacology 13.
Crossref
Crossref
Chung-Pu Wu, Ya-Ju Hsieh, Han-Yu Tseng, Yang-Hui Huang, Yan-Qing Li, Tai-Ho Hung, Shun-Ping Wang & Yu-Shan Wu. (2022) The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2. Biomedicine & Pharmacotherapy 154, pages 113663.
Crossref
Crossref
Negar Sarhangi, Shahrzad Hajjari, Seyede Fatemeh Heydari, Maryam Ganjizadeh, Fatemeh Rouhollah & Mandana Hasanzad. (2022) Breast cancer in the era of precision medicine. Molecular Biology Reports 49:10, pages 10023-10037.
Crossref
Crossref
Maria Krchniakova, Silvia Paukovcekova, Petr Chlapek, Jakub Neradil, Jan Skoda & Renata Veselska. (2022) Thiosemicarbazones and selected tyrosine kinase inhibitors synergize in pediatric solid tumors: NDRG1 upregulation and impaired prosurvival signaling in neuroblastoma cells. Frontiers in Pharmacology 13.
Crossref
Crossref
Chung-Pu Wu, Megumi Murakami, Yu-Shan Wu, Chun-Ling Lin, Yan-Qing Li, Yang-Hui Huang, Tai-Ho Hung & Suresh V. Ambudkar. (2022) The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biomedicine & Pharmacotherapy 149, pages 112922.
Crossref
Crossref
Ashish Shah, Chhagan Patel, Ghanshaym Parmar, Ashish Patel & Manav Jain. (2022) A Concise Review on Tyrosine Kinase Targeted Cancer Therapy. Current Drug Therapy 17:2, pages 96-107.
Crossref
Crossref
Chung-Pu Wu, Yan-Qing Li, Ya-Chen Chi, Yang-Hui Huang, Tai-Ho Hung & Yu-Shan Wu. (2021) The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. International Journal of Molecular Sciences 22:17, pages 9440.
Crossref
Crossref
Chung-Pu Wu, Megumi Murakami, Yu-Shan Wu, Ya-Chen Chi, Sung-Han Hsiao, Yang-Hui Huang, Tai-Ho Hung & Suresh V. Ambudkar. (2021) Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Chung-Pu Wu, Tai-Ho Hung, Sabrina Lusvarghi, Yi-Hsuan Chu, Sung-Han Hsiao, Yang-Hui Huang, Yu-Tzu Chang & Suresh V. Ambudkar. (2021) The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biochemical Pharmacology 188, pages 114516.
Crossref
Crossref
Iago Dillion Lima Cavalcanti & José Cleberson Santos SoaresIago Dillion Lima Cavalcanti & José Cleberson Santos Soares. 2021. Advances in Cancer Treatment. Advances in Cancer Treatment
57
78
.
Chung-Pu Wu, Tai-Ho Hung, Sung-Han Hsiao, Yang-Hui Huang, Lang-Cheng Hung, Yi-Jou Yu, Yu-Tzu Chang, Shun-Ping Wang & Yu-Shan Wu. (2020) Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. Cancers 12:6, pages 1366.
Crossref
Crossref
Maria Krchniakova, Jan Skoda, Jakub Neradil, Petr Chlapek & Renata Veselska. (2020) Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration. International Journal of Molecular Sciences 21:9, pages 3157.
Crossref
Crossref
Xin Li, Kejing Zhang, Yu Hu & Na Luo. (2020) ERRα activates SHMT2 transcription to enhance the resistance of breast cancer to lapatinib via modulating the mitochondrial metabolic adaption. Bioscience Reports 40:1.
Crossref
Crossref
Chung-Pu Wu, Sung-Han Hsiao, Yang-Hui Huang, Lang-Cheng Hung, Yi-Jou Yu, Yu-Tzu Chang, Tai-Ho Hung & Yu-Shan Wu. (2020) Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. Cancers 12:1, pages 195.
Crossref
Crossref
Shaoyan Lin, Jian Yue, Xiuwen Guan, Peng Yuan, Jiayu Wang, Yang Luo, Ying Fan, Ruigang Cai, Qiao Li, Shanshan Chen, Pin Zhang, Qing Li, Fei Ma & Binghe Xu. (2019)
Polymorphisms of
MTHFR
and
TYMS
predict capecitabine‐induced hand‐foot syndrome in patients with metastatic breast cancer
. Cancer Communications 39:1, pages 1-12.
Crossref
Crossref
Jiani Wang & Binghe Xu. (2019) Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduction and Targeted Therapy 4:1.
Crossref
Crossref
Zhen Xiang, Shuzheng Song, Zhenggang Zhu, Wenhong Sun, Jaron E. Gifts, Sam Sun, Qiushi Shauna Li, Yingyan Yu & Keqin Kathy Li. (2019) LncRNAs GIHCG and SPINT1-AS1 Are Crucial Factors for Pan-Cancer Cells Sensitivity to Lapatinib. Frontiers in Genetics 10.
Crossref
Crossref
Shaocong Wu & Liwu Fu. (2018) Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. Molecular Cancer 17:1.
Crossref
Crossref
Hang Zhang, Yuxi Wang, Yangping Wu, Xiaohua Jiang, Yiran Tao, Yuqin Yao, Yujia Peng, Xiangzheng Chen, Yuyin Fu, Lin Yu, Ruixue Wang, Qinhuai Lai, Weirong Lai, Wenting Li, Yuhuan Kang, Shuli Yi, Ying Lu, Lantu Gou, Min Wu & Jinliang Yang. (2017) Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer. Signal Transduction and Targeted Therapy 2:1.
Crossref
Crossref
Jiliang Shen, Yaping Zhang, Hong Yu, Bo Shen, Yuelong Liang, Renan Jin, Xiaolong Liu, Liang Shi & Xiujun Cai. (2016) Role of DUSP1/MKP1 in tumorigenesis, tumor progression and therapy. Cancer Medicine 5:8, pages 2061-2068.
Crossref
Crossref
. (2015) Capecitabine/lapatinib. Reactions Weekly 1534:1, pages 41-41.
Crossref
Crossref
Mukesh Verma. (2014) Molecular profiling and companion diagnostics: where is personalized medicine in cancer heading?. Personalized Medicine 11:8, pages 761-771.
Crossref
Crossref